OR WAIT null SECS
The agreement gives Sanofi access to Biomunex’s proprietary bi- and multi-specific-antibody-generating platform.
On Jan. 15, 2019, Biomunex Pharmaceuticals, a Paris, France-based biopharmaceutical company specializing in bi- and multi-specific antibody immuno-therapeutics created from its next-generation proprietary BiXAb platform, announced that it has entered into a licensing agreement with Sanofi. This agreement is the first of its kind for Biomunex.
Under the agreement, Sanofi will have access to Biomunex's proprietary technology to generate and optimize bi- and multi-specific antibody therapeutics. Sanofi will be solely responsible for research, development, manufacturing, and global commercialization activities. Biomunex will receive an initial upfront payment and will be eligible to receive further clinical, regulatory, and commercial milestone payments. Financial terms of the transaction were not disclosed.
“This licensing agreement is a major milestone for Biomunex. It demonstrates the high value of the BiXAb technology and is the starting point for our collaboration strategy with pharmaceutical companies to discover and develop cutting-edge bi- and multi-specific antibodies, giving patients new treatment options,” said Pierre-Emmanuel Gerard, MD, founder and CEO of Biomunex, in a company press release. “We believe that the proceeds from this deal, together with the funding round that we expect to finalize in the near future, will help us accelerate the development of Biomunex’s proprietary BiXAb bi- and multi-specific antibody programs in immuno-oncology and other therapeutic areas towards clinical development.”
Biomunex’s BiXAb platform generates next-generation bi- and multi-specific antibodies. The technology allows the use of any pair of monospecific monoclonal antibodies for building blocks, with minimal engineering. The technology can develop immuno-oncology drug candidates with high anti-tumor activity and is also suitable for generating innovative bi- and multi-specific antibodies in other therapeutic areas, such as immune-mediated inflammatory and infectious diseases.
Source: Biomunex Pharmaceuticals